KEI and UACT Comments to NIH on License to T-Cell Therapy for Cancer to Ziopharm Oncology

(Update: The NIH provided a response to our comments on November 15, 2019) On Friday October 18, 2019, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) submitted comments on the “Prospective Grant of an Exclusive Patent License:… Continue Reading

KEI and UACT Comments to NIH on License in AAV Vectors to Generation Bio and Spark Therapeutics

On Friday October 11, 2019, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) submitted comments to the Federal Register notice (84 FR 51171) for the “Prospective Grant of Exclusive Patent License: Capsid-Free AAV Vectors, Compositions, and Methods… Continue Reading

WTO TRIPS Council: Submission of South Africa on R&D Costs and Pricing of Medicines and Health Technologies

On Friday, 4 October 2019, the World Trade Organization (WTO) published a submission by the Republic of South Africa on “R&D Costs and Pricing of Medicines and Health Technologies” (IP/C/W/659). In this paper, South Africa requested the WTO TRIPS Council… Continue Reading

UK Labour Party’s new pledge on innovation and affordability of medicines: Medicine for the Many

The UK Labour Party Document, “Medicines-For-The-Many” is 52 pages long, including 9 pages of end notes. It is an ambitious document. The document discusses, in some detail, innovation as well as access and affordability. The reforms proposed include measures that… Continue Reading

U.K. Labour Leader Jeremy Corbyn calls for use of compulsory licensing, public sector manufacturing and pricing controls on drugs using government funded inventions

Today, in his address to the U.K. Labour party conference, Labour Leader Jeremy Corbyn made the following statement on drug patents and prices. Yesterday I met Luis Walker, a wonderful nine-year-old boy. Luis is living with cystic fibrosis. Every day… Continue Reading